Elżbieta Jasińska

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study

Robert T. Naismith, Annette Wundes, Tjalf Ziemssen et al. · CNS Drugs · 2020 · 130 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage

Massimo Filippi, Maria A. Rocca, Elisabetta Pagani et al. · Journal of Neurology Neurosurgery & Psychiatry · 2013 · 113 citations

Life Sciences, Neurology, Neuroscience +17

Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study

Sibyl Wray, Florian Then Bergh, Annette Wundes et al. · Advances in Therapy · 2022 · 36 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies — the Polish experience

Agata Czarnowska, Waldemar Brola, Olga Zajkowska et al. · Neurologia i Neurochirurgia Polska · 2021 · 35 citations · Full text

Medicine, Infectious Diseases, Neurology +8